These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 16082383)
1. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma. Ren XW; Liang M; Meng X; Ye X; Ma H; Zhao Y; Guo J; Cai N; Chen HZ; Ye SL; Hu F Cancer Gene Ther; 2006 Feb; 13(2):159-68. PubMed ID: 16082383 [TBL] [Abstract][Full Text] [Related]
2. Conditionally replicative adenovirus vector carrying TRAIL gene for enhanced oncolysis of human hepatocellular carcinoma. Ye X; Lu Q; Zhao Y; Ren Z; Ren XW; Qiu QH; Tong Y; Liang M; Hu F; Chen HZ Int J Mol Med; 2005 Dec; 16(6):1179-84. PubMed ID: 16273304 [TBL] [Abstract][Full Text] [Related]
3. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766 [TBL] [Abstract][Full Text] [Related]
4. [Killing effect of Ad.TERT-TRAIL on tumor cell lines and its mechanism]. Tang YX; Chen Y; Gu JF; Qi R; Zou WG; Jiang LL; Liu XY Ai Zheng; 2005 May; 24(5):536-42. PubMed ID: 15890093 [TBL] [Abstract][Full Text] [Related]
5. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637 [TBL] [Abstract][Full Text] [Related]
6. Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated oncolytic adenovirus armed with TRAIL gene. Cao X; Yang M; Wei RC; Zeng Y; Gu JF; Huang WD; Yang DQ; Li HL; Ding M; Wei N; Zhang KJ; Xu B; Liu XR; Qian QJ; Liu XY Gene Ther; 2011 Aug; 18(8):765-77. PubMed ID: 21412282 [TBL] [Abstract][Full Text] [Related]
7. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Jacob D; Davis J; Zhu H; Zhang L; Teraishi F; Wu S; Marini FC; Fang B Clin Cancer Res; 2004 May; 10(10):3535-41. PubMed ID: 15161713 [TBL] [Abstract][Full Text] [Related]
8. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma. Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790 [TBL] [Abstract][Full Text] [Related]
9. Enhanced TRAIL sensitivity by E1A expression in human cancer and normal cell lines: inhibition by adenovirus E1B19K and E3 proteins. Hu B; Zhu H; Qiu S; Su Y; Ling W; Xiao W; Qi Y Biochem Biophys Res Commun; 2004 Dec; 325(4):1153-62. PubMed ID: 15555548 [TBL] [Abstract][Full Text] [Related]
10. Cancer gene therapy using a novel secretable trimeric TRAIL. Kim CY; Jeong M; Mushiake H; Kim BM; Kim WB; Ko JP; Kim MH; Kim M; Kim TH; Robbins PD; Billiar TR; Seol DW Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin]. Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284 [TBL] [Abstract][Full Text] [Related]
12. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor-related apoptosis-inducing ligand gene virotherapy. Zhang Y; Gu J; Zhao L; He L; Qian W; Wang J; Wang Y; Qian Q; Qian C; Wu J; Liu XY Cancer Res; 2006 Apr; 66(8):4291-8. PubMed ID: 16618754 [TBL] [Abstract][Full Text] [Related]
13. Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector. Guan M; Rodriguez-Madoz JR; Alzuguren P; Gomar C; Kramer MG; Kochanek S; Prieto J; Smerdou C; Qian C Cancer Res; 2006 Feb; 66(3):1620-9. PubMed ID: 16452221 [TBL] [Abstract][Full Text] [Related]
14. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL. Liu X; Cao X; Wei R; Cai Y; Li H; Gui J; Zhong D; Liu XY; Huang K Cancer Gene Ther; 2012 Jan; 19(1):49-57. PubMed ID: 21979578 [TBL] [Abstract][Full Text] [Related]
15. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Lin T; Gu J; Zhang L; Huang X; Stephens LC; Curley SA; Fang B Cancer Res; 2002 Jul; 62(13):3620-5. PubMed ID: 12097263 [TBL] [Abstract][Full Text] [Related]
16. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Wohlfahrt ME; Beard BC; Lieber A; Kiem HP Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719 [TBL] [Abstract][Full Text] [Related]
17. Potent antitumor effect of TRAIL mediated by a novel adeno-associated viral vector targeting to telomerase activity for human hepatocellular carcinoma. Wang Y; Huang F; Cai H; Zhong S; Liu X; Tan WS J Gene Med; 2008 May; 10(5):518-26. PubMed ID: 18338833 [TBL] [Abstract][Full Text] [Related]
18. [Construction and study of replication-defective adenovirus targeting hepatocarcinoma]. Xu DY; Du ZY; Wang Y; Chen HH; Xu YJ; Lu YL Ai Zheng; 2006 Jul; 25(7):798-804. PubMed ID: 16831267 [TBL] [Abstract][Full Text] [Related]
19. E1A sensitizes cancer cells to TRAIL-induced apoptosis through enhancement of caspase activation. Shao R; Lee DF; Wen Y; Ding Y; Xia W; Ping B; Yagita H; Spohn B; Hung MC Mol Cancer Res; 2005 Apr; 3(4):219-26. PubMed ID: 15831675 [TBL] [Abstract][Full Text] [Related]
20. Different apoptotic regulation of TRAIL-caspase pathway in HBV- and HCV-related hepatocellular carcinoma. Yano Y; Hayashi Y; Nakaji M; Nagano H; Seo Y; Ninomiya T; Yoon S; Wada A; Hirai M; Kim SR; Yokozaki H; Kasuga M Int J Mol Med; 2003 Apr; 11(4):499-504. PubMed ID: 12632104 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]